Jpmorgan Chase & CO Embecta Corp. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Embecta Corp. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 145,269 shares of EMBC stock, worth $2.94 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

145,269

Previous 143,669 1.11%

Holding current value

$2.94 Million

Previous $1.8 Million 14.09%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$11.46 - $16.56 $18,336 - $26,495	1,600 Added 1.11%	145,269 $2.05 Million
Q2 2024 Aug 12, 2024	BUY	$10.13 - $14.6 $346,283 - $499,086	34,184 Added 31.22%	143,669 $1.8 Million
Q1 2024 May 10, 2024	BUY	$12.35 - $19.33 $406,858 - $636,807	32,944 Added 43.04%	109,485 $1.45 Million
Q4 2023 Feb 12, 2024	SELL	$12.87 - $19.09 $269,034 - $399,057	-20,904 Reduced 21.45%	76,541 $1.45 Million
Q3 2023 Nov 14, 2023	SELL	$15.0 - $22.17 $126,435 - $186,870	-8,429 Reduced 7.96%	97,445 $1.47 Million
Q2 2023 Aug 11, 2023	BUY	$21.6 - $30.69 $297,928 - $423,307	13,793 Added 14.98%	105,874 $2.29 Million
Q1 2023 May 18, 2023	BUY	$23.07 - $32.77 $1.66 Million - $2.36 Million	72,155 Added 362.11%	92,081 $2.59 Million
Q1 2023 May 11, 2023	SELL	$23.07 - $32.77 $4.62 Million - $6.57 Million	-200,474 Reduced 90.96%	19,926 $560,000
Q4 2022 Feb 13, 2023	BUY	$25.29 - $35.48 $64,489 - $90,473	2,550 Added 1.17%	220,400 $5.57 Million
Q3 2022 Nov 14, 2022	SELL	$24.0 - $33.42 $3.13 Million - $4.36 Million	-130,483 Reduced 37.46%	217,850 $6.27 Million
Q2 2022 Aug 11, 2022	BUY	$24.78 - $33.36 $8.63 Million - $11.6 Million	348,333 New	348,333 $8.82 Million

Others Institutions Holding EMBC

# of Institutions

405

Shares Held

51.1M

Call Options Held

162K

Put Options Held

61K

View Full List

About Embecta Corp.

Ticker EMBC
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 57,836,500
Market Cap $1.17B
Description
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to whole...

More about EMBC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Embecta Corp. Transaction History